secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2026-10-19T20:05:20+00:00
Accession:  0001104659-26-116876
Event type: litigation
Sentiment:  positive
Materiality: 0.70
Item codes: 1.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Collegium pays Grünenthal $17M to settle Nucynta ER patent suit and terminate 2015 license
--------------------------------------------------------------------------------

- Collegium paid Grünenthal $17,000,000 to resolve the Nucynta Litigation, a patent suit Grünenthal filed in February 2026 in the U.S. District Court for New Jersey.
- The October 15, 2026 Settlement Agreement terminates the 2015 Grünenthal License and the Consent Agreement in the Territory, discharging all royalty obligations.
- Grünenthal assigned certain Nucynta Products patents to Collegium and filed a motion to dismiss the Nucynta Litigation.
- The Consent Agreement otherwise continues in full force and effect; the report was signed by EVP and CFO Colleen Tupper on October 19, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/0001104659-26-116876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/tm2627827d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-116876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer